Entering text into the input field will update the search result below

Healthcare ratings round up

  • Retrophin (RTRX +3.7%) rated Outperform with a $48 (98% upside) price target by Leerink Partners.
  • OvaScience (OVAS-OLD +8.7%) rated Outperform with a $60 (82% upside) price target by Oppenheimer.
  • OxiGENE (OXGN -0.7%) rated Buy with a $6 (314% upside) price target by H.C. Wainwright.
  • Esperion Therapeutics (ESPR -4.5%) rated Buy with a $140 (40% upside) price target by UBS.
  • Trevena (TRVN -2.3%) rated Outperform with a $15 (110% upside) price target by Wedbush.
  • NewLink Genetics (NLNK -2.3%) downgraded to Hold with a $50 (4% downside risk) price target by Jefferies.
  • Stryker (SYK +0.2%) downgraded to Underweight with a $92 (1% upside) price target by Barclays.
  • Universal Health Services (UHS +2.7%) downgraded to Underperform with a $98 (16% downside risk) price target by Sterne Agee.

Recommended For You

About TVTX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
TVTX--
Travere Therapeutics, Inc.